RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Canntab Therapeutics Stock

Canntab Therapeutics EBIT 2024

Canntab Therapeutics EBIT

-3.6 M CAD

Ticker

PILL.CN

ISIN

CA1377991023

WKN

A2JKBY

In 2024, Canntab Therapeutics's EBIT was -3.6 M CAD, a 8% increase from the -3.33 M CAD EBIT recorded in the previous year.

The Canntab Therapeutics EBIT history

YEAREBIT (undefined CAD)
2022-3,597.35
2021-3,330.76
2020-2,615.71
2019-2,501.77
2018-1,665.81
2017-188
2016630.84
2015-170
2014-
2013-630
2012-1,560
2011-1,450
2010-100

Canntab Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Canntab Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Canntab Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Canntab Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Canntab Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Canntab Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Canntab Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Canntab Therapeutics’s growth potential.

Canntab Therapeutics Revenue, EBIT and net profit per share

DateCanntab Therapeutics RevenueCanntab Therapeutics EBITCanntab Therapeutics Net Income
2022293,360 undefined-3.6 M undefined-3.69 M undefined
20210 undefined-3.33 M undefined-4.42 M undefined
2020133,330 undefined-2.62 M undefined-2.61 M undefined
2019240,000 undefined-2.5 M undefined-2.46 M undefined
201841,680 undefined-1.67 M undefined-2.41 M undefined
20170 undefined-188,000 undefined-182,450 undefined
2016942,360 undefined630,840 undefined519,780 undefined
20150 undefined-170,000 undefined-170,000 undefined
20140 undefined0 undefined0 undefined
20130 undefined-630,000 undefined-300,000 undefined
20120 undefined-1.56 M undefined-1.56 M undefined
201110,000 undefined-1.45 M undefined-1.45 M undefined
20100 undefined-100,000 undefined-100,000 undefined

Canntab Therapeutics stock margins

The Canntab Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Canntab Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Canntab Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Canntab Therapeutics's sales revenue. A higher gross margin percentage indicates that the Canntab Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Canntab Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Canntab Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Canntab Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Canntab Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Canntab Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Canntab Therapeutics Margin History

Canntab Therapeutics Gross marginCanntab Therapeutics Profit marginCanntab Therapeutics EBIT marginCanntab Therapeutics Profit margin
202223.68 %-1,226.26 %-1,257.56 %
202123.68 %0 %0 %
202023.68 %-1,961.83 %-1,955.48 %
201923.68 %-1,042.4 %-1,024.41 %
201823.68 %-3,996.67 %-5,778.34 %
201723.68 %0 %0 %
201623.68 %66.94 %55.16 %
201523.68 %0 %0 %
201423.68 %0 %0 %
201323.68 %0 %0 %
201223.68 %0 %0 %
201123.68 %-14,500 %-14,500 %
201023.68 %0 %0 %

Canntab Therapeutics Aktienanalyse

What does Canntab Therapeutics do?

Canntab Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Canntab Therapeutics's EBIT

Canntab Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Canntab Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Canntab Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Canntab Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Canntab Therapeutics stock

How much did Canntab Therapeutics achieve in EBIT for the current year?

In the current year, Canntab Therapeutics has achieved an EBIT of -3.6 M CAD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Canntab Therapeutics.

How has the EBIT of Canntab Therapeutics developed in recent years?

The EBIT of Canntab Therapeutics has increased by 8.004% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Canntab Therapeutics?

The EBIT of Canntab Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Canntab Therapeutics pay?

Over the past 12 months, Canntab Therapeutics paid a dividend of 2.9 CAD . This corresponds to a dividend yield of about 58,000 %. For the coming 12 months, Canntab Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Canntab Therapeutics?

The current dividend yield of Canntab Therapeutics is 58,000 %.

When does Canntab Therapeutics pay dividends?

Canntab Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Canntab Therapeutics?

Canntab Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Canntab Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Canntab Therapeutics located?

Canntab Therapeutics is assigned to the '-' sector.

Wann musste ich die Aktien von Canntab Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Canntab Therapeutics from 4/30/2016 amounting to 0.015 CAD, you needed to have the stock in your portfolio before the ex-date on 3/8/2016.

When did Canntab Therapeutics pay the last dividend?

The last dividend was paid out on 4/30/2016.

What was the dividend of Canntab Therapeutics in the year 2023?

In the year 2023, Canntab Therapeutics distributed 0 CAD as dividends.

In which currency does Canntab Therapeutics pay out the dividend?

The dividends of Canntab Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Canntab Therapeutics

Our stock analysis for Canntab Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Canntab Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.